CL2014002430A1 - Uso del compuesto r-p88 (metabolito activo de iloperidona en su forma enantiomerica r) para tratar una enfermedad psiquiatrica tal como esquizofrenia, trastorno bipolar, depresion, autismo, entre otras, cuando se administra una vez al dia; y composicion farmaceutica que comprende el compuesto r-p88. - Google Patents
Uso del compuesto r-p88 (metabolito activo de iloperidona en su forma enantiomerica r) para tratar una enfermedad psiquiatrica tal como esquizofrenia, trastorno bipolar, depresion, autismo, entre otras, cuando se administra una vez al dia; y composicion farmaceutica que comprende el compuesto r-p88.Info
- Publication number
- CL2014002430A1 CL2014002430A1 CL2014002430A CL2014002430A CL2014002430A1 CL 2014002430 A1 CL2014002430 A1 CL 2014002430A1 CL 2014002430 A CL2014002430 A CL 2014002430A CL 2014002430 A CL2014002430 A CL 2014002430A CL 2014002430 A1 CL2014002430 A1 CL 2014002430A1
- Authority
- CL
- Chile
- Prior art keywords
- compound
- iloperidone
- autism
- schizophrenia
- depression
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 2
- 206010003805 Autism Diseases 0.000 title 1
- 208000020706 Autistic disease Diseases 0.000 title 1
- 208000020925 Bipolar disease Diseases 0.000 title 1
- XMXHEBAFVSFQEX-UHFFFAOYSA-N iloperidone Chemical class COC1=CC(C(C)=O)=CC=C1OCCCN1CCC(C=2C3=CC=C(F)C=C3ON=2)CC1 XMXHEBAFVSFQEX-UHFFFAOYSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 208000020016 psychiatric disease Diseases 0.000 title 1
- 201000000980 schizophrenia Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261610664P | 2012-03-14 | 2012-03-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2014002430A1 true CL2014002430A1 (es) | 2015-04-17 |
Family
ID=48407766
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2014002430A CL2014002430A1 (es) | 2012-03-14 | 2014-09-12 | Uso del compuesto r-p88 (metabolito activo de iloperidona en su forma enantiomerica r) para tratar una enfermedad psiquiatrica tal como esquizofrenia, trastorno bipolar, depresion, autismo, entre otras, cuando se administra una vez al dia; y composicion farmaceutica que comprende el compuesto r-p88. |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US10874659B2 (enExample) |
| EP (2) | EP3345603B1 (enExample) |
| JP (5) | JP2015510893A (enExample) |
| KR (2) | KR20140121487A (enExample) |
| CN (2) | CN108938632A (enExample) |
| AU (2) | AU2013232014B2 (enExample) |
| BR (1) | BR112014022687A8 (enExample) |
| CA (1) | CA2865845C (enExample) |
| CL (1) | CL2014002430A1 (enExample) |
| CO (1) | CO7091183A2 (enExample) |
| ES (2) | ES2677474T3 (enExample) |
| IL (1) | IL234412B (enExample) |
| IN (1) | IN2014DN08495A (enExample) |
| MX (1) | MX374067B (enExample) |
| RU (1) | RU2651710C2 (enExample) |
| WO (1) | WO2013138602A1 (enExample) |
| ZA (1) | ZA201406369B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102870956B1 (ko) | 2015-02-17 | 2025-10-16 | 반다 파마슈티칼즈, 인코퍼레이티드. | 조현병의 치료를 위한 일로페리돈 |
| US11214827B2 (en) | 2018-08-30 | 2022-01-04 | Vanda Pharmaceuticals Inc. | Genetic markers for enhancing efficacy of antipsychotic treatment with iloperidone |
| EP4637768A1 (en) * | 2022-12-19 | 2025-10-29 | Vanda Pharmaceuticals Inc. | Dosage regime of iloperidone for treating bipolar i disorder and schizophrenia |
| CN121218989A (zh) * | 2023-06-02 | 2025-12-26 | 万达制药公司 | 使用伊潘立酮的治疗方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5364866A (en) | 1989-05-19 | 1994-11-15 | Hoechst-Roussel Pharmaceuticals, Inc. | Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics |
| US7029694B2 (en) | 2000-04-26 | 2006-04-18 | Watson Laboratories, Inc. | Compositions and methods for transdermal oxybutynin therapy |
| WO2003020707A1 (en) | 2001-08-31 | 2003-03-13 | Novartis Ag | Optical isomers of an iloperidone metabolite |
| US20050059006A1 (en) | 2001-12-10 | 2005-03-17 | Sridhar Kudaravalli | Methods of treating psychosis and schizophrenia based on polymorphisms in the cntf gene |
| TW200410955A (en) | 2002-07-29 | 2004-07-01 | Altana Pharma Ag | Novel salt of (S)-PANTOPRAZOLE |
| GB0322994D0 (en) * | 2003-10-01 | 2003-11-05 | Novartis Ag | Organic compounds |
| WO2006039663A2 (en) | 2004-09-30 | 2006-04-13 | Vanda Pharmaceuticals, Inc | Methods for the administration of iloperidone |
| US20100063093A1 (en) * | 2007-03-28 | 2010-03-11 | Curt Wolfgang | Methods for the administration of iloperidone |
| AU2007253684A1 (en) * | 2006-05-22 | 2007-11-29 | Vanda Pharmaceuticals, Inc. | Treatment for depressive disorders |
| WO2008121899A2 (en) | 2007-03-29 | 2008-10-09 | Vanda Pharmaceuticals Inc. | Method of predicting a predisposition to qt prolongation |
| WO2009036100A2 (en) | 2007-09-10 | 2009-03-19 | Vanda Pharmaceuticals, Inc. | Prediction of qt prolongation based on snp genotype |
| US9328387B2 (en) | 2007-09-10 | 2016-05-03 | Vanda Pharmaceuticals, Inc. | Antipsychotic treatment based on SNP genotype |
| EP2416779B1 (en) | 2009-04-06 | 2016-03-09 | Vanda Pharmaceuticals Inc. | Method of predicting a predisposition to qt prolongation based on bai3 gene sequence or product thereof |
| CA2757717C (en) | 2009-04-06 | 2018-09-04 | Vanda Pharmaceuticals, Inc. | Method of predicting a predisposition to qt prolongation |
| EP2416778B1 (en) | 2009-04-06 | 2016-03-02 | Vanda Pharmaceuticals Inc. | Method of predicting a predisposition to qt prolongation based on abcc2 gene sequence or product thereof |
| HUE037724T2 (hu) | 2009-04-06 | 2018-09-28 | Vanda Pharmaceuticals Inc | Eljárás a KCNQ1 gén polimorfizmusán alapuló kezelésre |
| EP2430183B1 (en) | 2009-05-15 | 2014-12-17 | Vanda Pharmaceuticals Inc. | Antipsychotic treatment based on drd2 or ankk1 snp genotype |
-
2013
- 2013-03-14 BR BR112014022687A patent/BR112014022687A8/pt not_active Application Discontinuation
- 2013-03-14 RU RU2014141112A patent/RU2651710C2/ru active
- 2013-03-14 JP JP2015500615A patent/JP2015510893A/ja active Pending
- 2013-03-14 EP EP18152636.9A patent/EP3345603B1/en active Active
- 2013-03-14 AU AU2013232014A patent/AU2013232014B2/en active Active
- 2013-03-14 KR KR1020147026434A patent/KR20140121487A/ko not_active Ceased
- 2013-03-14 CN CN201810683727.2A patent/CN108938632A/zh active Pending
- 2013-03-14 IN IN8495DEN2014 patent/IN2014DN08495A/en unknown
- 2013-03-14 MX MX2014010989A patent/MX374067B/es active IP Right Grant
- 2013-03-14 ES ES13721817.8T patent/ES2677474T3/es active Active
- 2013-03-14 EP EP13721817.8A patent/EP2825167B1/en active Active
- 2013-03-14 ES ES18152636T patent/ES2773711T3/es active Active
- 2013-03-14 KR KR1020177001093A patent/KR20170008327A/ko not_active Ceased
- 2013-03-14 CA CA2865845A patent/CA2865845C/en active Active
- 2013-03-14 CN CN201380013841.XA patent/CN104203240A/zh active Pending
- 2013-03-14 WO PCT/US2013/031413 patent/WO2013138602A1/en not_active Ceased
- 2013-03-14 US US14/384,401 patent/US10874659B2/en active Active
-
2014
- 2014-08-29 ZA ZA2014/06369A patent/ZA201406369B/en unknown
- 2014-09-01 IL IL234412A patent/IL234412B/en active IP Right Grant
- 2014-09-12 CL CL2014002430A patent/CL2014002430A1/es unknown
- 2014-10-09 CO CO14224666A patent/CO7091183A2/es unknown
-
2016
- 2016-05-30 AU AU2016203591A patent/AU2016203591B2/en active Active
- 2016-11-07 JP JP2016217680A patent/JP2017061506A/ja active Pending
-
2018
- 2018-09-10 JP JP2018169090A patent/JP7151029B2/ja active Active
-
2020
- 2020-09-28 JP JP2020162569A patent/JP2021001221A/ja active Pending
- 2020-09-30 US US17/039,769 patent/US20210015809A1/en not_active Abandoned
-
2022
- 2022-12-01 JP JP2022192922A patent/JP2023022243A/ja active Pending
-
2023
- 2023-09-26 US US18/373,205 patent/US20240016791A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2014000170A (es) | Compuestos de imidazopirrolidinona | |
| ME03323B (me) | Paraziticidne oralne veterinarske kompozicije koje sadrže sistemski djelujuća aktivna sredstva, metodi i primjene istih | |
| MX382411B (es) | Soluciones midriáticas y antiinflamatorias inyectables, estables y libres de conservantes. | |
| CL2014000517A1 (es) | Compuestos derivados de heterociclos nitrogenados condensados, moduladores de pi3k; composicion farmaceutica; y uso en el tratamiento de una enfermedad tal como asma, lupus, osteoartritis, esclerosis multiple, cancer, entre otras. | |
| CL2014002726A1 (es) | Compuestos derivados de pirrolopirimidina y purina; composicion farmaceutica; utiles en el tratamiento del cancer (div. sol. 566-14). | |
| CL2015000711A1 (es) | Compuestos derivados de bis(fluoroalquil)-1,4-benzodiazepinona como inhibidores de notch; composicion farmaceutica y uso en el tratamiento del cancer. | |
| CL2015001731A1 (es) | Compuestos inhibidores de autotaxina; composicion y combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como fibrosis, prurito, cancer, entre otras. | |
| UY35040A (es) | Pirrolopirimidinilamino-benzotiazolonas sustituidas | |
| GT201300215A (es) | Inhibidores de glucosilceramida sintasa | |
| CO7151483A2 (es) | Jeringa | |
| CL2014002757A1 (es) | Compuestos derivados de benzamida para inhibir la actividad de abl1, abl2 y bcr-abl1, composicion farmaceutica; y uso en el tratamiento del cancer. | |
| FI20116138A7 (fi) | Matriisi bioaktiivisten aineiden hallittuun vapauttamiseen | |
| AR084057A1 (es) | Composiciones para el cuidado de telas | |
| PE20150631A1 (es) | Formas cristalinas de un modulador del receptor androgenico | |
| CL2014000447A1 (es) | Compuestos derivados de piridina y pirimidina sustituidos, mediadores de quinurenina-3-monooxigenasa; composiciones farmaceuticas que los comprenden; y uso en el tratamiento de una patologia neurodegenerativa, tal como la enfermedad de huntington. | |
| CU24159B1 (es) | Una nueva composición terapéutica que contiene apomorfina como principio activo | |
| BR112016005417A8 (pt) | "compostos derivados de desoxinojirimicina, composição farmacêutica e seus usos" | |
| UY35848A (es) | Tienopirimidinas | |
| CL2015000891A1 (es) | Compuestos derivados de fenil-etinilo, moduladores de la actividad del receptor mglur5; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de la ansiedad, dolor, depresion,entre otras. | |
| LT2939665T (lt) | Farmacinė kompozicija, skirta živ infekcijų gydymui | |
| CO6920289A2 (es) | Composición farmacéutica oftalmológica tópica que contiene regorafenib. | |
| CO6592109A2 (es) | Nueva forma cristalina de un derivado de ciclopropilbenzamida | |
| CL2014002430A1 (es) | Uso del compuesto r-p88 (metabolito activo de iloperidona en su forma enantiomerica r) para tratar una enfermedad psiquiatrica tal como esquizofrenia, trastorno bipolar, depresion, autismo, entre otras, cuando se administra una vez al dia; y composicion farmaceutica que comprende el compuesto r-p88. | |
| AR078323A1 (es) | Tratamiento con fampridina de liberacion sostenida en pacientes con esclerosis multiple | |
| PE20151300A1 (es) | Composicion antifungica topica para el tratamiento de onicomicosis |